Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation

Table 8

Analyses of prognostic impact of quantitative and semiquantitative immunohistological estimates, as obtained from the pretreatment biopsies (number of patients analyzed shown in brackets).

	Survival^a		Recurrence^b
	no pre-chemotherapy	+pre-chemotherapy	no pre-chemotherapy	+pre-chemotherapy
	P-values^c		P-values^c
Angiogenesis^d	.90	.92	.23	.76
	(65)	(30)	(65)	(35)
Proliferation rate (%)	.56	.52	.82	.54
	(70)	(46)	(65)	(42)
Proliferation index (mm^−2)	.47	.81	.43	.89
	(70)	(46)	(65)	(42)
p53 expression (%)	.18	.29	.43	.11
	(70)	(46)	(65)	(42)
p53 index (mm^−2)	.73	.99	.90	.90
	(70)	(46)	(65)	(42)
MDR/Pgp	.43	.12	.23	.16
	(70)	(46)	(65)	(42)

^aAnalysis based on disease-specific mortality, and for continuous parameters divided on the median, whereas for MDR/Pgp divided in a chemotherapy-sensitive group (score <2) and a chemotherapy-resistant group (score ≥2).
^bAll kinds of recurrences, but patients with persistent, progressive disease after primary therapy have been deleted from the analyses.
^c𝑃-values as reported from log-rank tests.
^dAngiogenesis could not be estimated in 21 cases due to technical, immunohistological problems, see text.